Trial Profile

An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenvatinib (Primary)
Indications Carcinoma; Thyroid cancer
Focus Therapeutic Use
Sponsors Eisai Inc

Most Recent Events

07 May 2021 Final and Interim analysis results published in the Journal of Clinical Oncology
26 Oct 2018 Status changed from active, no longer recruiting to discontinued.
10 May 2018 This trial has been Discontinued in Italy, according to European Clinical Trials Database

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com